• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » WaveRx goes under after FDA-weary investors pull the plug

WaveRx goes under after FDA-weary investors pull the plug

August 19, 2011 By MassDevice staff

WaveRx

WaveRx Inc.’s head slipped under the water forever, a victim of its backers’ doubts about the FDA ever giving a green light to its technology for treating diabetic neuropathy.

Mark Wan, a founding partner at Three Arch Partners, told the VentureWire blog that his VC company and its two other partners in WaveRx, 5AM Ventures and Polaris Venture Partners, shut the taps last year after waiting for an answer from the FDA’s Center for Devices & Biological Health about its proposal for a re-vamped clinical trial.

Initially founded five years ago to pursue treatments for nail and skin disorders, WaveRx pulled good and bad news out of its first clinicals, examining the technology for treating the toenail fungus onychomycosis, Wan told the blog. The company’s device, which used electro-stimulation and microwaves, proved to be a minor improvement over other treatments for onychomycosis, but some subjects in the trial who suffered from diabetic neuropathy showed "marked improvement" after receiving the WaveRx treatment, according to VentureWire.

The company ran another trial examining the treatment for diabetic neuropathy and passed the results along to the CDRH.

"This was a multi-center, sham controlled, double-blind study," Wan told the blog.

That means each arm of the trial was conducted in separate clinical settings, with the control group receiving "sham" placebo treatments and the study cohort receiving the WaveRx treatment.

But after examining the trial results, the FDA asked for more information, inaugurating "an ongoing cycle of back and forth" about the next set of trials, Wan told VentureWire.

"We as investors said ‘enough,’" he said. "We can’t keep funding this company to an unknown endpoint."

WaveRx drummed up $500,000 in an equity offering in April 2010, according to a regulatory filing, adding that to the $6.8 million kitty it had already raised.

An email to the CDRH seeking comment was not immediately returned.

Filed Under: News Well, Wall Street Beat Tagged With: Venture Capital/Private Equity, WaveRx Inc.

More recent news

  • China reportedly launches country’s first invasive BCI trial
  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy